Utility of proGRP as a tumor marker in the medullary thyroid carcinoma

Marina Parra‐Robert, Aida Orois, Josep M. Augé, Irene Halperín, Xavier Filella, Rafael MolinaClinical 2016 · DOI

Abstract

The low prevalence of this malignancy strongly recommends further collaborative studies, mainly focused on monitoring proGRP during tyrosine kinase inhibitors treatment for early detection of resistance and assessing its usefulness to avoid the observed false positive fluctuations that occur with CT and CEA.
BibTeX
@inproceedings{parrarobert2016utility,
  author = {Marina Parra‐Robert and Aida Orois and Josep M. Augé and Irene Halperín and Xavier Filella and Rafael Molina},
  title = {{Utility of proGRP as a tumor marker in the medullary thyroid carcinoma}},
  booktitle = {Clinical},
  year = {2016},
  doi = {10.1515/cclm-2016-0572},
}

Loading related content...

Figure